Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Magic_Truffle
gptkb:Psychonaut gptkb:Center_for_Psychedelic_and_Consciousness_Research |
| gptkbp:affects |
hallucinations
altered perception enhanced emotional experiences |
| gptkbp:associated_with |
mushrooms of the genus Psilocybe
|
| gptkbp:composed_of |
tryptophan
|
| gptkbp:cultural_significance |
used in traditional medicine
used in shamanic practices used in indigenous cultures |
| gptkbp:discovered_by |
gptkb:Albert_Hofmann
1950s |
| gptkbp:duration |
4 to 6 hours
|
| gptkbp:historical_source |
certain mushrooms
|
| https://www.w3.org/2000/01/rdf-schema#label |
Psilocybin
|
| gptkbp:ingredients |
C12 H17 N2 O4 P
|
| gptkbp:is_found_in |
gptkb:magic_mushrooms
|
| gptkbp:is_influential_in |
introspection
time distortion synesthesia visual distortions ego dissolution |
| gptkbp:is_used_for |
treatment for OCD
treatment for PTSD treatment for addiction treatment for cluster headaches treatment for existential distress |
| gptkbp:legal_issue |
varies by country
|
| gptkbp:manager |
oral
|
| gptkbp:mass |
284.25 g/mol
|
| gptkbp:metabolism |
gptkb:psilocin
|
| gptkbp:notable_work |
Imperial College London studies
Johns Hopkins studies NYU studies |
| gptkbp:premiered_on |
20 to 40 minutes
|
| gptkbp:previous_name |
3-(2-dimethylaminoethyl)-1 H-indol-4-yl dihydrogen phosphate
|
| gptkbp:related_to |
gptkb:psilocin
|
| gptkbp:research_areas |
psychiatry
|
| gptkbp:research_focus |
neuroplasticity
cognitive flexibility mystical experiences mood enhancement brain connectivity |
| gptkbp:safety_features |
generally considered safe in controlled settings
|
| gptkbp:scientific_classification |
Schedule I substance in the US
|
| gptkbp:side_effect |
anxiety
dizziness nausea confusion |
| gptkbp:used_in |
gptkb:award
gptkb:spiritual_practices end-of-life anxiety treatment therapy for anxiety therapy for depression |